(SYBX) Synlogic, Inc. Business Model Canvas Research

Clinical trial sites are core partners for Synlogic, Inc.'s Phase I and Phase II work because they handle patient screening, dosing, and safety monitoring. In rare diseases, where each U.S. condition affects fewer than 200,000 people, and in oncology, these hospital and clinic links are what make small, high-touch studies possible.

• Run screening and enrollment
• Manage dosing and follow-up
• Track safety signals in real time
• Support rare-disease and oncology trials

Synlogic, Inc. relied on specialty investigators in metabolic disease and oncology to shape trial design and read out clinical data for its PKU, homocystinuria, hyperoxaluria, and solid tumor programs. Their input was critical because these are rare, high-complexity studies where small patient sets and biomarker-driven endpoints can change the result.

• Protocol design for rare-disease trials
• Clinical data interpretation and endpoint readout
• Expertise across 4 core programs

Rare-disease studies often run in small cohorts of 10 to 40 patients, so biomarker and clinical data analysis is key for Synlogic, Inc. It tracks pharmacodynamic readouts, efficacy, safety, and dose response, then supports go/no-go calls between stages.

• Small cohorts raise signal noise
• Biomarkers show target engagement
• Data guides dose and progression

Synlogic’s regulatory and trial operations center on FDA-facing work: protocol submissions, safety reporting, and study oversight for its clinical programs. With no approved products and a small team, tight execution matters because even one delayed filing or report can slow development and raise burn.

• FDA submissions and amendments
• Adverse-event safety reporting
• Trial site and data oversight
• Lean ops reduce cash burn

Synlogic, Inc. relied on a partnership network with Roche and Ginkgo Bioworks to add drug-development, manufacturing, and synthetic-biology know-how without building it all in-house. In a capital-heavy biotech market, Roche reported CHF 60.5 billion in 2025 sales, showing the scale and credibility these links can bring.

These ties acted as strategic resources: they lowered execution risk, widened access to specialized tools, and strengthened partner trust in a field where one failed program can burn millions.

• Roche adds scale and credibility
• Ginkgo Bioworks adds platform capability
• Shared risk matters in biotech

Synlogic’s Cambridge, Massachusetts base puts it in the heart of the Kendall Square biotech cluster, with direct access to MIT, Harvard, hospitals, and venture capital. That location helps it recruit scientific talent fast and work closely with researchers and investors. Cambridge is a key resource because proximity speeds hiring and collaboration.

• Boston-area biotech talent pool
• Near MIT and Harvard
• Closer to investors and partners

Synlogic, Inc. has five named programs in its 2026 development work, so value is not tied to one asset. That mix spreads risk across indications and stages, and a broader pipeline can lift the odds that at least one program creates meaningful value.

• Five named programs
• More indication coverage
• Stage diversification reduces single-asset risk
• Broader pipeline raises success odds

Synlogic, Inc. builds engineered live medicines, using synthetic biotic therapeutics instead of small molecules to act locally in the gut and trigger novel mechanisms. As of the latest filings, Company had no commercial product revenue, so the value rests on platform differentiation, not marketed sales.

• Local action, not systemic exposure
• Novel biology versus standard pharma
• Platform-led, pre-revenue model

Academic and clinical investigators were Synlogic, Inc.’s key relationship holders because small rare-disease studies can hinge on each safety readout and efficacy signal. Their feedback from 2025-era early trials helped refine protocols, dose steps, and next-step plans as teams judged whether to advance or stop a program.

• Investigators interpret early safety signals
• Small cohorts magnify each data point
• Feedback shapes protocol changes fast

Synlogic’s rare-disease outreach must build trust in tiny, active groups: PKU affects about 1 in 10,000-15,000 births, homocystinuria about 1 in 200,000-335,000, and primary hyperoxaluria about 1-3 per million. Patient education helps drive trial enrollment and later adoption, because informed families are easier to reach and more likely to stay engaged.

• Small, high-trust patient groups
• Education supports trial enrollment
• Awareness speeds future adoption

Synlogic, Inc. used Roche and Ginkgo as partner channels to reach buyers and technical know-how beyond its internal team. These ties mattered because Synlogic’s latest public filings before its wind-down showed only about $15.1 million in cash at 2023 year-end, so outside support was key for development, scale, and later market access.

• Roche: commercial reach
• Ginkgo: technical scale-up
• Partners cut internal load

Scientific publications, posters, and conference talks are key channels for Synlogic, Inc. because they build trust in rare disease and oncology, where peer review matters; rare diseases affect about 300 million people worldwide, so early clinical and platform data need clear, credible proof points.

These channels also help Synlogic, Inc. reach regulators, investigators, and partners fast, especially when sharing first-in-human or proof-of-concept results from small studies.

• Builds scientific credibility
• Supports rare disease trust
• Shares early clinical data
• Reaches partners and KOLs

SYNB1891’s Phase I program for solid tumors and lymphoma creates a distinct oncology customer segment, separate from Synlogic, Inc.’s rare metabolic disease base. This segment is anchored in specialist cancer centers, where early-stage immuno-oncology trials are run and patient access is concentrated.

• Phase I oncology use case
• Solid tumors and lymphoma
• Specialist cancer centers drive access

Specialist prescribers and treatment centers are the key gatekeepers for Synlogic, Inc. They decide trial use and later adoption, so metabolic specialists and oncologists matter most for any clinical-stage pipeline. Synlogic, Inc. reported no commercial product revenue in its last public filings, which makes these early clinical decision-makers even more central.

• Metabolic specialists drive trial enrollment
• Oncologists can speed future uptake
• Centers shape protocol execution

Synlogic, Inc. must still fund FDA, quality, safety, and legal controls, and these costs usually climb as a program moves from preclinical work into clinical trials and filing stages. In 2024, after Synlogic, Inc. began winding down operations, its active development burden shrank, but any regulated biotech still carries ongoing pharmacovigilance and compliance overhead.

• FDA and quality systems are fixed costs.
• Trial reporting raises compliance spend.
• Legal and safety duties add ongoing burn.

General and administrative costs are Synlogic, Inc.’s public-company overhead: finance, legal, HR, audit, and investor relations, plus IP protection and board governance. These are support costs, not data-generating work, so they weigh on SG&A and cash burn even when pipeline activity is light.

• Finance, legal, HR, IR
• IP and governance costs
• Support, not direct output

That cost base matters because every extra public-company layer adds fixed expense, while the platform still needs capital to fund research. For Synlogic, the key signal is how tightly it can keep G&A aligned with the latest filed period’s operating scale.

Synlogic used licensing and option fees to turn synthetic-biology programs into early cash, often before full development handoff. In its last public filings, the Company reported no product revenue, so this model mattered because biotech option deals can pay upfront while shifting later R&D and commercial risk to a partner.

• Upfront cash before full handoff
• Common in biotech partnering
• No product revenue reported

Synlogic, Inc. has no current commercial product sales; as a clinical-stage company, future revenue would only come if a product wins approval, then direct sales could start. Under partnering deals, royalties could add another stream, but today this remains pre-revenue and future-oriented.

• No current product sales
• Approval could unlock direct revenue
• Partnerships may bring royalties
• Revenue is still future-based